Fluorescent and Lanthanide Labeling for Ligand Screens, Assays, and Imaging

Methods in Molecular Biology

Volumn 716, Issue , 2011, Pages 89-126

  Josan, Jatinder S ^a   De Silva, Channa R ^a   Yoo, Byunghee ^a   Lynch, Ronald M ^b   Pagel, Mark D ^a   Vagner, Josef ^b   Hruby, Victor J ^a  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cy5; DELFIA; DOTA; DTPA; Dual modal agents; Heteromultivalent ligands,Lanthaligands; PARACEST MRI; Solid phase synthesis; Targeted imaging agents

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CHELATING AGENT; FLUORESCENT DYE; LANTHANIDE; LIGAND; PENTETIC ACID; SINGLE HETEROCYCLIC RINGS;

ANIMAL; ARTICLE; BINDING SITE; CELL LINE; CHEMISTRY; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; SYNTHESIS;

ANIMALS; BINDING SITES; CELL LINE; CHELATING AGENTS; FLUORESCENT DYES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LANTHANOID SERIES ELEMENTS; LIGANDS; MAGNETIC RESONANCE IMAGING; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; NEOPLASMS; PENTETIC ACID;

EID: 79956226035     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-012-6_6     Document Type: Chapter

References (49)

1. Josan, J. S., Vagner, J., Handl, H. L., Sankaranarayanan, R., Gillies, R. J., and Hruby, V. J. (2008) Solid-phase synthesis of heterobivalent ligands targeted to melanocortin and cholecystokinin receptors. Int J Pep Res Ther. 14: 293–300.
2. Vagner, J., Xu, L., Handl, H., Josan, J. S., Morse, D. L., Mash, E. A., Gillies, R. J., and Hruby, V. J. (2008) Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed. 47: 1685–1688.
3. Xu, L., Vagner, J., Josan, J., Lynch, R. M., Morse, D. L., Baggett, B., Han, H., Mash, E. A., Hruby, V. J., and Gillies, R. J. (2009) Enhanced targeting with heterobivalent ligands. Mol Cancer Ther. 8: 2356–2365.
4. Sokolov, K., Follen, M., and Richards-Kortum, R. (2002) Optical spectroscopy for detection of neoplasia. Curr Opin Chem Biol. 6: 651–658.
5. Ballou, B., Ernst, L. A., and Waggoner, A. S. (2005) Fluorescence imaging of tumors in vivo. Curr Med Chem. 12: 795–805.
6. Frangioni, J. V. (2003) In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 7: 626–634.
7. Sevick-Muraca, E. M., Houston, J. P., and Gurfinkel, M. (2002) Fluorescence-enhanced, near infrared diagnostic imaging with contrast agents. Curr Opin Chem Biol. 6: 642–650.
8. Mujumdar, R. B., Ernst, L. A., Mujumdar, S. R., Lewis, C. J., and Waggoner, A. S. (1993) Cyanine dye labeling reagents: sulfoindocya-nine succinimidyl esters. Bioconjug Chem. 4: 105–111.
9. Handl, H. L., Vagner, J., Yamamura, H., Hruby, V. J., and Gillies, R. J. (2004) Lanthanide-based time-resolved fluorescence of in cyto ligand–receptor interactions. Anal Biochem. 330: 242–250.
10. Handl, H. L., and Gillies, R. J. (2005) Lanthanide-based luminescent assays for ligand-receptor interactions. Life Sci. 77: 361–371.
11. Pandya, S., Yu, J., and Parker, D. (2006) Engineering emissive europium and terbium complexes for molecular imaging and sensing. Dalton Trans. 23: 2757–2766.
12. Selvin, P. (2002) Principles and biophysical applications of lanthanide-based probes. Annu Rev Biophys Biomol Struct. 31: 275–302.
13. Steinkamp, T., and Karst, U. (2004) Detection strategies for bioassays based on luminescent lanthanide complexes and signal amplification. Anal Bioanal Chem. 380: 24–30.
14. Parker, D. (2004) Excitement in f block: structure, dynamics and function of nine-coordinate chiral lanthanide complexes in aqueous media. Chem Soc Rev. 33: 156–165.
15. Thunus, L., and Lejeune, R. (1999) Overview of transition metal and lanthanide complexes as diagnostic tools. Coord Chem Rev. 184: 125–155.
16. Josan, J. S., Morse, D. L., Xu, L., Trissal, M., Baggett, B., Davis, P., Vagner, J., Gillies, R. J., and Hruby, V. J. (2009) Solid-phase synthetic strategy and bioevaluation of a Labeled d-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett. 11: 2479–2482.
17. Handl, H. L., Vagner, J., Yamamura, H. I., Hruby, V. J., and Gillies, R. J. (2005) Development of a lanthanide-based assay for detection of receptor–ligand interactions at the d-opioid receptor. Anal Biochem. 343: 299–307.
18. De-Silva, C. R., Vagner, J., Lynch, R., Gillies, R. J., and Hruby, V. J. (2010) Optimization of time-resolved fluorescence assay for detection of Eu-DOTA labeled ligand-receptor interactions. Anal Biochem. 398: 15–23.
19. Leon-Rodriguez, L. M. D., and Kovacs, Z. (2008) The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem. 19: 391–402.
20. Uusijärvi, H., Bernhardt, P., Rösch, F., Maecke, H. R., and Forssell-Aronsson, E. (2006) Electron-and positron-emitting radi-olanthanides for therapy: aspects of dosimetry and production. J Nucl Med. 47: 807–814.
21. Merbach, A. F., and Toth, E. (2001) The chemistry of contrast agents in medical magnetic resonance imaging. Wiley, New York.
22. Zhang, S., Merritt, M., Woessner, D. E., Lenkinski, R. E., and Sherry, A. D. (2003) PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res. 36: 783–790.
23. Aime, S., Barge, A., Delli Castelli, D., Fedeli, F., Mortillaro, A., Nielsen, F. U., and Terreno, E. (2002) Paramagnetic lanthanide (III) complexes as pH sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med. 47: 639–648.
24. Yoo, B., Sheth, V., and Pagel, M. D. (2009) An amine-derivatized, DOTA-loaded polymeric support for Fmoc solid phase peptide synthesis. Tet Lett. 50: 4459–4462.
25. Ali, M. M., Liu, G., Shah, T., Flask, C. A., and Pagel, M. D. (2009) Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Acc Chem Res. 42: 915–924.
26. Yoo, B., and Pagel, M. D. (2008) An overview of responsive MRI contrast agents for molecular imaging. Front Biosci. 13: 1733–1752.
27. Yoo, B., and Pagel, M. D. (2006) A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc. 128: 14032–14033.
28. Yoo, B., Raam, M., Rosenblum, R., and Pagel, M. D. (2007) Enzyme-responsive PARACEST MRI contrast agents: a new biomedical imaging approach for studies of the proteasome. Contrast Media Mol Imaging. 2: 189–198.
29. Grieco, P., Lavecchia, A., Cai, M., Trivedi, D., Weinberg, D., MacNeil, T., Van der Ploeg, L. H., and Hruby, V. J. (2002) Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. J Med Chem. 45: 5287–5294.
30. 2+ from cell populations. Meth Mol Biol. 114: 287–306.
31. Edwards, W. B., Fields, C. G., Anderson, C. J., Pajeau, T. S., Welch, M. J., and Fields, G. B. (1994) Generally applicable, convenient solid-phase synthesis and receptor affinities of oct-reotide analogs. J Med Chem. 37: 3749–3757.
32. Krchnák, V., Vágner, J., and Lebl, M. (1988) Noninvasive continuous monitoring of solid-phase peptide synthesis by acid-base indicator. Int J Pept Prot Res. 32: 415–416.
33. Bräse, S., Kirchhoff, J. H., and Köbberling, J. (2003) Palladium-catalysed reactions in solid phase organic synthesis. Tetrahedron. 59: 885–939.
34. a-Alloc temporary protection in solid-phase peptide synthesis. The use of amine–borane complexes as allyl group scavengers. J Chem Soc Perkin Trans. 1: 2871–2874.
35. Williams, R. M., Aldous, D. J., and Aldous, S. C. (1990) General synthesis of b, g-alkynylg-lycine derivatives. J Org Chem. 55: 4657–4663.
36. Moore, D. A. (2008) Selective trialkylation of cyclen with tert-butyl bromoacetate. Org Synth. 85: 10–14.
37. Ali, M., Yoo, B., and Pagel, M. D. (2009) Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol Pharm. 6: 1409–1416.
38. Liu, G., Ali, M. M., Yoo, B., Griswold, M. A., Tkach, J. A., and Pagel, M. D. (2009) PARACEST MRI with improved temporal resolution. Magn Reson Med. 61: 399–408.
39. Liu, G., Li, Y., and Pagel, M. D. (2007) Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn Reson Med. 58: 1249–1256.
40. Josan, J. S. (2008) Heteromultivalent ligands directed targeting of cell-surface receptors – implications in cancer diagnostics & therapeutics. Ph.D. dissertation. The University of Arizona, Tucson.
41. Dakubu, S. (1992) Method of determining a biological substance involving labelling with a metal chelate. US Patent 5,124,268.
42. 3.2TOPO. Forensic Sci Int. 99: 5–23.
43. Albericio, F., Annis, I., Royo, M., and Barany, G. (2000) Preparation and handling of peptides containing methionine and cysteine. In: Chan, W. C., White P. D. (eds) Fmoc solid phase peptide synthesis, 1st ed., Oxford University Press, Oxford, pp 77–114.
44. Annis, I., Hargittai, B., and Barany, G. (1997) Disulfide bond formation in peptides. Meth Enzymol. 289: 198–221.
45. Chen, L., Annis, I., and Barany, G. (2001) Disulfide bond formation in peptides. Curr Protocols Prot Sci. 18.16.11–18.16.19.
46. nd ed., Oxford University Press, Oxford, pp 93–219.
47. Gisin, B. F. (1972) The monitoring of reactions in solid-phase peptide synthesis with picric acid. Anal Chim Acta. 58: 248–249.
48. Rowatt, E., and Williams, R. J. (1989) The interaction of cations with the dye Arsenazo III. Biochem J. 259: 295–298.
49. Barge, A., Cravotto, G., Gianolio, E., and Fedeli, F. (2006) How to determine free Gd and free ligand in solution of Gd chelates. A technical note. Contrast Media Mol Imaging. 1: 184–188.